Fol. Biol. 2005, 51, 19-24
Immunotherapeutic Efficacy of Vaccines Generated by Fusion of Dendritic Cells and HPV16-Associated Tumour Cells
Utilization of vaccines generated by fusion of dendritic cells and tumour cells is a promising approach to tumour immunotherapy. We have examined the therapeutic efficacy of vaccines generated by fusion of HPV16-associated tumour cells TC-1 with syngeneic and allogeneic dendritic cells. Locally administered hybrid cells generated by fusion of MHC class I+ TC-1 cells and syngeneic DC inhibited the growth of MHC class I+ TC-1 tumours, but not the growth of MHC class I- TC-1/A9-derived tumours. The growth of TC-1 tumours was also inhibited by hybrids generated by fusion of TC-1 cells and allogeneic DC. The therapeutic efficacy was enhanced by co-administration of the vaccine with synthetic immunostimulatory ODN CpG 1826.
Keywords
Funding
This work was supported by grants Nos. IAA50522203 and AVOZ50520514 from the Grant Agency of the Academy of Sciences of the Czech Republic, by grant No. 301/04/0492 from the Grant Agency of the Czech Republic and by the League Against Cancer, Prague.
References
Copyright
This is an open-access article distributed under the terms of the Creative Commons Attribution License.